Results 51 to 60 of about 3,003 (174)
eVLP‐Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation
Small, Volume 22, Issue 1, 2 January 2026.Engineered virus‐like particles (eVLPs) are used to deliver Cas9 nuclease to knock out tissue factor (TF) and plasminogen activator inhibitor‐1 (PAI‐1) genes in pancreatic islets. The edited islets maintained viability and function, while reducing instant blood‐mediated inflammatory reaction (IBMIR) markers and improving glycemic control in diabetic ...
Manju Shrestha +6 more
wiley +1 more source
, 2011 Hirudin is the most potent natural inhibitor of thrombin and a powerful anticoagulant. Large-scale production of recombinant hirudin is desirable for therapy.
Qing Gang Xu +5 more
core +1 more source
Annals of Translational Medicine, 2019 This study aimed to investigate the efficacy and safety of simvastatin plus hirudin in preventing atherosclerosis in the patients with early type 2 diabetes mellitus (T2DM).This was a 24-week, randomized, open-label and controlled study in which 150 outpatients initially diagnosed with T2DM were randomly assigned into either simvastatin (40 mg daily at
De-Qiang, Li +5 more
openaire +2 more sources
New Advances in Biologic Treatment for Malignant Atrophic Papulosis: A Systematic Review
Dermatologic Therapy, Volume 2026, Issue 1, 2026.Background Malignant atrophic papulosis (MAP) is the systemic subtype of Degos disease, characterized by high lethality. Currently there is no standardized treatment protocol. Steroids and immunosuppressive therapies result in limited effectiveness. Biologic treatments offer promising therapeutic potential for MAP and significantly improve prognosis ...
Jia-Wei Liu +3 more
wiley +1 more source
The Emergency Use of Recombinant Hirudin in Cardiopulmonary Bypass
, 2005 The most common anticoagulant used for cardiopumonary bypass is heparin. An alternate form of anticoagulant therapy is needed for patients who have immune-mediated heparin-associated thrombocytopenia (HIT).
Debra S. Douglass +3 more
core +1 more source
A comparison of recombinant Hirudin with Heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators [PDF]
, 1996 BACKGROUND: Thrombin has a pivotal role in the pathogenesis of acute coronary thrombosis. We compared the clinical efficacy of a potent, direct thrombin inhibitor, recombinant hirudin, with that of heparin (an indirect antithrombin agent) in patients ...
Simoons, M.L. (Maarten)
core
MedComm, Volume 6, Issue 11, November 2025.Summary of PCSK9 inhibitor mechanisms. PCSK9 inhibitors (PCSK9‐i) primarily lower LDL‐cholesterol (LDL‐C) by blocking PCSK9‐mediated degradation of hepatic LDL receptors (LDLR), enhancing LDL clearance. Beyond LDLR‐dependent effects, PCSK9‐i exert multiple benefits via LDLR‐independent pathways.
Jia Kuang +3 more
wiley +1 more source
Microbial Biotechnology, Volume 18, Issue 11, November 2025.The centromeric sequences of Ogataea polymorpha, a methylotrophic non‐conventional yeast, were characterised for the first time and support the development of new genetically stable centromeric plasmids with high genetic stability and compatibility, providing powerful genetic toolboxes for the synthetic biology and metabolic engineering‐driven ...
Yanfei Cheng +5 more
wiley +1 more source
, 1998 Objectives. We sought to show that hirudin might interact differently with streptokinase (SK) and tissue-type plasminogen activator (t-PA), which could reduce the incidence of death or reinfarction at 30 days.Background.
Simes, R.John +19 more
core +1 more source
Emerging Strategies for Platelet‐Modified Nanoparticles in Targeted Tumor Therapy
Advanced NanoBiomed Research, Volume 5, Issue 10, October 2025.This review highlights innovative strategies using platelet‐modified nanoparticles to target tumors more precisely. By mimicking platelet functions, these biomimetic carriers improve tumor homing, enhance drug delivery, and reduce immune clearance.
Chunyu Bai +5 more
wiley +1 more source